BioSpace News Archive

Business

Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time

Jaguar Health announced today that it will host a conference call on Tuesday, November 14, 2017 at 4:30 p.m. Eastern Time to review year-to-date sales figures for Jaguar and Napo Pharmaceuticals, Inc. (Napo).

November 9, 2017

·

5 min read

Business

Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

For the third quarter of 2017, the Company reported a net loss of $15.3 million, or a net loss of $0.68 per share (basic and diluted), compared to a net loss of $8.1 million, or a net loss of $14.22 per share for the same period in 2016.

November 9, 2017

·

9 min read

Business

IntelGenx Reports Third Quarter 2017 Financial Results

Total revenues for the three-month period ended September 30, 2017 amounted to $1.3 million, compared to $1.8 million for the three-month period ended September 30, 2016.

November 9, 2017

·

5 min read

Drug Development

IntelGenx Submits Montelukast VersaFilm Clinical Trial Application With Health Canada

IntelGenx announced that it has submitted a clinical trial application (“CTA”) to Health Canada for approval to initiate its Phase 2a proof of concept (“POC”) study with Montelukast in mild to moderate Alzheimer’s Disease (“AD”).

November 9, 2017

·

4 min read

Business

ContraFect Announces Third Quarter 2017 Financial Results

This quarter, ContraFect completed a public stock offering raising net proceeds of $37.1 million.

November 9, 2017

·

10 min read

Business

Athenex Announces Third Quarter 2017 Results

Revenue for the three months ended September 30, 2017 was $14.0 million, an increase of $8.4 million, or 149%, as compared to $5.6 million for the three months ended September 30, 2016.

November 9, 2017

·

13 min read

Business

Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results

Loss from operations was $(5.7) million in the third quarter of 2017, compared to $(6.6) million in the third quarter of 2016.

November 9, 2017

·

9 min read

Pharm Country

Helius Medical Technologies Announces Positive Results from its Registrational Clinical Trial for Traumatic Brain Injury (TBI)

The trial evaluated the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS) for the treatment of subjects with chronic balance deficits due to mild-to-moderate TBI.

November 9, 2017

·

8 min read

Business

Ossur Hf: Management Changes

Kim de Roy has been appointed EVP of R&D and will become a member of Össur’s Executive Management.

November 9, 2017

·

1 min read

Drug Development

Bavarian Nordic Announces Initiation of Phase II Booster Study of its Universal RSV Vaccine

This study is designed to help determine whether a single shot administration of vaccine is required annually, or if it remains effective over multiple seasons.

November 9, 2017

·

3 min read